Home

Cameron Turtle

CIK 1758363 · Chief Executive Officer · last filed 2026-07-02

Cameron Turtle is a Chief Executive Officer who has filed 48 SEC Form 4 insider transactions across 6 companies since 2019. The most recent filing shows the insider sold $1.3M of SYRE on Jul 2, 2026. Across all open-market trades the lifetime net is −$19.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $61.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$60.97M

Companies

6

Total Filings

48

Lifetime Open-Market Net

-$19.10M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SYRE Chief Executive Officer 582,540 $99.96 $58.23M -$7.25M 13 2026-07-02
DMRA Director — $29.42 — $0 1 2026-03-25
ORKA Director — $90.45 — $0 1 2025-06-03
Spyre Therapeutics, Inc. (AGLE) Delisted Chief Executive Officer 746,507 $12.01 $8.97M $0 1 2023-11-27
BBIO See Remarks 32,068 $85.55 $2.74M -$3.63M 15 2020-12-29
Eidos Therapeutics, Inc. (EIDX) Delisted Chief Business Officer 73,159 — — -$8.21M 13 2020-12-16

Recent Filings

48 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-02 SYRE Sell (S) −15,000 -$1.32M EDGAR
2026-07-01 SYRE Notice (144) −45,000 -$4.00M EDGAR
2026-06-03 SYRE Sell (S) −15,000 -$1.06M EDGAR
2026-05-01 SYRE Sell (S) −15,000 -$1.07M EDGAR
2026-04-03 SYRE Sell (S) −15,000 -$739.9K EDGAR
2026-03-25 DMRA Grant (A) — $0 EDGAR
2026-03-03 SYRE Sell (S) −15,000 -$632.9K EDGAR
2026-03-02 SYRE Notice (144) −60,000 -$2.58M EDGAR
2026-02-04 SYRE Sell (S) −15,000 -$492.0K EDGAR
2026-01-13 SYRE Grant (A) — $0 EDGAR
Showing 1–10 of 48
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.